Your browser doesn't support javascript.
loading
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons, Mark; Liu, Michelle; Stober, Carol; Pond, Gregory; Jemaan Alzahrani, Mashari; Ong, Michael; Ernst, Scott; Booth, Christopher; Mates, Mihaela; Abraham Joy, Anil; Aseyev, Olexiy; Blanchette, Phillip; Vandermeer, Lisa; Tu, Megan; Thavorn, Kednapa; Fergusson, Dean.
Afiliación
  • Clemons M; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON K1H 8L6, Canada.
  • Liu M; Cancer Therapeutics Program, Ottawa Hospital Research Institute, 501 Smyth Road, Box 511, Ottawa, ON K1H 8L6, Canada.
  • Stober C; Cancer Therapeutics Program, Ottawa Hospital Research Institute, 501 Smyth Road, Box 511, Ottawa, ON K1H 8L6, Canada.
  • Pond G; Cancer Therapeutics Program, Ottawa Hospital Research Institute, 501 Smyth Road, Box 511, Ottawa, ON K1H 8L6, Canada.
  • Jemaan Alzahrani M; Department of Oncology, McMaster University, 699 Concession Street, Suite 4-204, Hamilton, ON L8V 5C2, Canada.
  • Ong M; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON K1H 8L6, Canada.
  • Ernst S; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON K1H 8L6, Canada.
  • Booth C; Division of Medical Oncology, Department of Oncology, London Regional Cancer Program, London Health Sciences Centre and University of Western Ontario, 800 Commissioners Road East, London, ON N6A 5W9, Canada.
  • Mates M; Cancer Centre of Southeastern Ontario, 25 King Street West, Kingston, ON K7L 5P9, Canada.
  • Abraham Joy A; Cancer Centre of Southeastern Ontario, 25 King Street West, Kingston, ON K7L 5P9, Canada.
  • Aseyev O; Division of Medical Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada.
  • Blanchette P; Regional Cancer Care Northwest, Thunder Bay Regional Health Sciences Centre, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada.
  • Vandermeer L; Division of Medical Oncology, Department of Oncology, London Regional Cancer Program, London Health Sciences Centre and University of Western Ontario, 800 Commissioners Road East, London, ON N6A 5W9, Canada.
  • Tu M; Cancer Therapeutics Program, Ottawa Hospital Research Institute, 501 Smyth Road, Box 511, Ottawa, ON K1H 8L6, Canada.
  • Thavorn K; Cancer Therapeutics Program, Ottawa Hospital Research Institute, 501 Smyth Road, Box 511, Ottawa, ON K1H 8L6, Canada.
  • Fergusson D; Clinical Epidemiology Program, Ottawa Hospital Research Institute, and the University of Ottawa, Ottawa, ON K1H 8L6, Canada.
J Bone Oncol ; 30: 100388, 2021 Oct.
Article en En | MEDLINE | ID: mdl-34567960
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Bone Oncol Año: 2021 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Bone Oncol Año: 2021 Tipo del documento: Article País de afiliación: Canadá